Clinical data | |
---|---|
Pronunciation | /ˌfoʊˈmɛpɪzoʊl/ |
Trade names | Antizol, others |
Other names | 4-Methylpyrazole |
AHFS/Drugs.com | Monograph |
License data |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.028.587 |
Chemical and physical data | |
Formula | C4H6N2 |
Molar mass | 82.106 g·mol−1 |
3D model (JSmol) | |
Density | 0.99 g/cm3 |
Boiling point | 204 to 207 °C (399 to 405 °F) (at 97,3 kPa) |
| |
|
Fomepizole, also known as 4-methylpyrazole, is a medication used to treat methanol and ethylene glycol poisoning.[4] It may be used alone or together with hemodialysis.[4] It is given by injection into a vein.[4]
Common side effects include headache, nausea, sleepiness, and unsteadiness.[4] It is unclear if use during pregnancy causes risk to a fetus.[4] Fomepizole works by blocking the enzyme that converts methanol and ethylene glycol to their toxic breakdown products.[4]
Fomepizole was approved for medical use in the United States in 1997.[4] It is on the World Health Organization's List of Essential Medicines.[5]